Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ORGANIZATION
ORGANIZATION
- FPMAJ Should Take Lead to Address Drug Supply Issues: JMA Chief
March 17, 2022
- Realistic Approach Should Be Taken for Supply Chain Surveys: JPMA Economic Security Taskforce
March 15, 2022
- Japan Drug Makers Launch Digital Health Advocacy Group, Mitsubishi Tanabe Exec Serves as Head
March 15, 2022
- Switch to Original Drugs Up Nearly 5-Fold YOY in 6-Month Period from August 2021: NPhA Survey
March 15, 2022
- API Import Costs from Europe Surging amid Russian Airspace Closures
March 15, 2022
- List of 180 Needed Drugs Compiled in Europe-Led Drive to Support Ukraine
March 14, 2022
- Therapeutic Value of Kampo Medicines for COVID-19 Being Examined
March 11, 2022
- Generic/Biosimilar Association Proposes Establishing Inspector Database to Stem GMP Violations
March 9, 2022
- Apply Only Market Price-Linked Rules in Next Off-Year Revision, No Hasty Debate for Adjustment Rate: JMA Official
March 8, 2022
- Antimicrobial Use Fell 30-40% Between January 2019 and January 2021: JPA
March 7, 2022
- JMA Calls for Investigation into Increasing Cases of Off-Label Use of GLP-1 Agents
March 4, 2022
- FPMAJ Starts Survey on Industry’s Inspection Status for “Stable Supply Medicines”
March 3, 2022
- JPMA, Overseas Pharma Groups Call for Improvements in Access to COVID-19 Vaccines
March 1, 2022
- Impact of Ukraine Invasion Limited in Japan? Trader Group Says Epirubicin Is Only API Possibly Affected
February 25, 2022
- FPMAJ Begins Survey on Lifting of Shipment Restrictions
February 24, 2022
- Chuikyo Payer Rep Wants Category-Based Debate on Adjustment Rate, Prods PMP Cuts in Next Off-Year Revision
February 24, 2022
- Takeda’s Ramona Sequeira Becomes 1st Female PhRMA Chair
February 15, 2022
- Govt-Industry Arrangement for Drug Supply Survey Hits Rough Waters; FPMAJ Stands Pat on Continued Dialogue
February 10, 2022
- PhRMA Taps Diplomat Hans Klemm as New Japan Representative
February 3, 2022
- Japan Market Should Grow in Single-Digit Range, Not Zero Growth: PhRMA Chair
January 31, 2022
ページ
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…